Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.
Looking for a particular Galecto, Inc. employee's phone or email?
Galecto, Inc. Questions
The Galecto, Inc. annual revenue was $13.5 million in 2026.
Anders Pedersen is the COO of Galecto, Inc..
9 people are employed at Galecto, Inc..
The NAICS codes for Galecto, Inc. are [325, 32541, 32, 3254].
The SIC codes for Galecto, Inc. are [28, 2834, 283].
Top Galecto, Inc. Employees
-
Anders Pedersen
COO at Galecto, Inc.
Copenhagen, DK1 -
11
-
Pia Jensen
Project Director at Galecto, Inc.
Copenhagen, Capital Region, Denmark -
Duncan Humphries
Senior Scientist at Galecto, Inc.
United Kingdom -
Jonathan Cummins
Director CMC at Galecto, Inc.
Didcot, Oxfordshire, United Kingdom1
Related Companies
